Cardiac salvage by tweaking with beta-3-Adrenergic Receptors

Cardiovascular Research

Volumn 111, Issue 2, 2016, Pages 128-133

  Balligand, Jean Luc ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Adrenergic receptor; Catecholamines; Heart failure; Hypertrophy; Nitric oxide; Remodelling

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; ACETANILIDE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; MIRABEGRON; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; THIAZOLE DERIVATIVE;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR TISSUE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION; ANIMAL; CARDIAC MUSCLE CELL; DRUG EFFECTS; ENDOTHELIUM CELL; HEART CONTRACTION; HEART DISEASES; HEART VENTRICLE REMODELING; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENDOTHELIAL CELLS; HEART DISEASES; HUMANS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE III; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION; THIAZOLES; VENTRICULAR REMODELING;

EID: 85007412360     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw056     Document Type: Review

References (50)

1. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-Adrenergic signaling in heart failure? Circ Res 2003;93:896-906.
2. Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation 2003;107:1100-1102.
3. Balligand JL. Beta3-Adrenoreceptors in cardiovasular diseases: new roles for an "old" receptor. Curr Drug Deliv 2013;10:64-66.
4. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD. Molecular characterization of the human beta 3-Adrenergic receptor. Science 1989;245:1118-1121.
5. Gauthier C, Langin D, Balligand JL. Beta3-Adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 2000;21:426-431.
6. Liggett SB, Freedman NJ, Schwinn DA, Lefkowitz RJ. Structural basis for receptor subtype-specific regulation revealed by a chimeric beta 3/beta 2-Adrenergic receptor. Proc Natl Acad Sci USA 1993;90:3665-3669.
7. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H. Functional beta3-Adrenoceptor in the human heart. J Clin Invest 1996;98:556-562.
8. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL. Endothelial beta3-Adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 2004; 110:948-954.
9. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of beta(3)-Adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 2001;103:1649-1655.
10. Amour J, Loyer X, Le GM, Mabrouk N, David JS, Camors E, Carusio N, Vivien B, Andriantsitohaina R, Heymes C, Riou B. Altered contractile response due to increased beta3-Adrenoceptor stimulation in diabetic cardiomyopathy: The role of nitric oxide synthase 1-derived nitric oxide. Anesthesiology 2007;107:452-460.
11. Dincer UD, Bidasee KR, Guner S, Tay A, Ozcelikay AT, Altan VM. The effect of diabetes on expression of beta1-, beta2-, and beta3-Adrenoreceptors in rat hearts. Diabetes 2001;50:455-461.
12. Vij M, Drake MJ. Clinical use of the beta3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome. Ther Adv Urol 2015;7:241-248.
13. Tagaya E, Tamaoki J, Takemura H, Isono K, Nagai A. Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cyclic adenosine monophosphatedependent pathway. Lung 1999;177:321-332.
14. Dessy C, Balligand JL. Beta3-Adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol 2010;59:135-163.
15. Kou R, Michel T. Epinephrine regulation of the endothelial nitric-oxide synthase: roles of RAC1 and beta3-Adrenergic receptors in endothelial NO signaling. J Biol Chem 2007; 282:32719-32729.
16. Edwards G, Feletou M, Weston AH. Endothelium-derived hyperpolarising factors and associated pathways: A synopsis. Pflugers Arch 2010;459:863-879.
17. Karimi GK, Liu CC, Garcia A, Fry NA, Hamilton EJ, Figtree GA, Rasmussen HH. beta3-Adrenoceptor activation relieves oxidative inhibition of the cardiac Na+-K+ pump in hyperglycemia induced by insulin receptor blockade. Am J Physiol Cell Physiol 2015;309:C286-C295.
18. Sorrentino SA, Doerries C, Manes C, Speer T, Dessy C, Lobysheva I, Mohmand W, Akbar R, Bahlmann F, Besler C, Schaefer A, Hilfiker-Kleiner D, Luscher TF, Balligand JL, Drexler H, Landmesser U. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional beta1- blockade. J Am Coll Cardiol 2011;57:601-611.
19. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL, Le Marec H. The negative inotropic effect of beta3-Adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 1998; 102:1377-1384.
20. Gauthier C, Tavernier G, Trochu JN, Leblais V, Laurent K, Langin D, Escande D, Le Marec H. Interspecies differences in the cardiac negative inotropic effects of beta(3)-Adrenoceptor agonists. J Pharmacol Exp Ther 1999;290:687-693.
21. Watts VL, Sepulveda FM, Cingolani OH, Ho AS, Niu X, Kim R, Miller KL, Vandegaer K, Bedja D, Gabrielson KL, Rameau G, O'Rourke B, Kass DA, Barouch LA. Antihypertrophic and anti-oxidant effect of beta3-Adrenergic stimulation in myocytes requires differential neuronal NOS phosphorylation. J Mol Cell Cardiol 2013;62:8-17.
22. Belge C, Hammond J, Dubois-Deruy E, Manoury B, Hamelet J, Beauloye C, Markl A, Pouleur AC, Bertrand L, Esfahani H et al. Enhanced expression of beta3-Adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation 2014;129:451-462.
23. Kruger M, Kotter S, Grutzner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, Linke WA. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 2009;104:87-94.
24. Skeberdis VA, Gendviliene V, Zablockaite D, Treinys R, Macianskiene R, Bogdelis A, Jurevicius J, Fischmeister R. beta3-Adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-Type Ca2+ current. J Clin Invest 2008;118: 3219-3227.
25. Treinys R, Zablockaite D, Gendviliene V, Jurevicius J, Skeberdis VA. beta(3)-Adrenergic regulation of L-Type Ca(2)(+) current and force of contraction in human ventricle. J Membr Biol 2014;247:309-318.
26. Imbrogno S, Gattuso A, Mazza R, Angelone T, Cerra MC. Beta3-AR and the vertebrate heart: A comparative view. Acta Physiol (Oxf) 2015;214:158-175.
27. Cheng HJ, Zhang ZS, Onishi K, Ukai T, Sane DC, Cheng CP. Upregulation of functional beta(3)-Adrenergic receptor in the failing canine myocardium. Circ Res 2001;89: 599-606.
28. Idigo WO, Reilly S, Zhang MH, Zhang YH, Jayaram R, Carnicer R, Crabtree MJ, Balligand JL, Casadei B. Regulation of endothelial nitric-oxide synthase (NOS) S-glutathionylation by neuronal NOS: evidence of a functional interaction between myocardial constitutive NOS isoforms. J Biol Chem 2012;287:43665-43673.
29. Angelone T, Filice E, Quintieri AM, Imbrogno S, Recchia A, Pulera E, Mannarino C, Pellegrino D, Cerra MC. Beta3-Adrenoceptors modulate left ventricular relaxation in the rat heart via the NO-cGMP-PKG pathway. Acta Physiol (Oxf) 2008;193:229-239.
30. Morimoto A, Hasegawa H, Cheng HJ, Little WC, Cheng CP. Endogenous beta3-Adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol 2004;286:H2425-H2433.
31. Donckier JE, Massart PE, Van Mechelen H, Heyndrickx GR, Gauthier C, Balligand JL. Cardiovascular effects of beta 3-Adrenoceptor stimulation in perinephritic hypertension. Eur J Clin Invest 2001;31:681-689.
32. Bundgaard H, Liu CC, Garcia A, Hamilton EJ, Huang Y, Chia KK, Hunyor SN, Figtree GA, Rasmussen HH. beta(3) adrenergic stimulation of the cardiac Na+-K+ pump by reversal of an inhibitory oxidative modification. Circulation 2010;122: 2699-2708.
33. Maier LS. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine. J Cardiovasc Pharmacol 2009;54: 279-286.
34. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 2003;83:59-115.
35. Dumas M, Dumas JP, Bardou M, Rochette L, Advenier C, Giudicelli JF. Influence of beta-Adrenoceptor agonists on the pulmonary circulation. Effects of a beta3-Adrenoceptor antagonist, SR 59230A. Eur J Pharmacol 1998;348:223-228.
36. Niu X, Watts VL, Cingolani OH, Sivakumaran V, Leyton-Mange JS, Ellis CL, Miller KL, Vandegaer K, Bedja D, Gabrielson KL, Paolocci N, Kass DA, Barouch LA. Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol 2012;59:1979-1987.
37. Trappanese DM, Liu Y, McCormick RC, Cannavo A, Nanayakkara G, Baskharoun MM, Jarrett H, Woitek FJ, Tillson DM, Dillon AR, Recchia FA, Balligand JL, Houser SR, Koch WJ, Dell'Italia LJ, Tsai EJ. Chronic beta1-Adrenergic blockade enhances myocardial beta3-Adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective beta1-blocker therapy. Basic Res Cardiol 2015;110:456.
38. Calvert JW, Condit ME, Aragon JP, Nicholson CK, Moody BF, Hood RL, Sindler AL, Gundewar S, Seals DR, Barouch LA, Lefer DJ. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of beta(3)-Adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res 2011;108: 1448-1458.
39. Aragon JP, Condit ME, Bhushan S, Predmore BL, Patel SS, Grinsfelder DB, Gundewar S, Jha S, Calvert JW, Barouch LA, Lavu M, Wright HM, Lefer DJ. Beta3-Adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. J Am Coll Cardiol 2011; 58:2683-2691.
40. Garcia-Prieto J, Garcia-Ruiz JM, Sanz-Rosa D, Pun A, Garcia-Alvarez A, Davidson SM, Fernandez-Friera L, Nuno-Ayala M, Fernandez-Jimenez R, Bernal JA, Izquierdo- Garcia JL, Jimenez-Borreguero J, Pizarro G, Ruiz-Caballo J, Macaya C, Fuster V, Yellon DM, Ibanez B. beta3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes. Basic Res Cardiol 2014;109:422.
41. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frerart F, Belge C, Jnaoui K, Noirhomme P, Feron O, Balligand JL. Endothelial beta3-Adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the thirdgeneration beta-blocker nebivolol. Circulation 2005;112:1198-1205.
42. Lim SL, Lam CS, Segers VF, Brutsaert DL, De Keulenaer GW. Cardiac endotheliummyocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. Eur Heart J 2015;36:2050-2060.
43. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ. Cold-Activated brown adipose tissue in healthy men. N Engl J Med 2009;360:1500-1508.
44. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009;360:1509-1517.
45. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J, Savisto NJ, Enerback S, Nuutila P. Functional brown adipose tissue in healthy adults. N Engl J Med 2009;360:1518-1525.
46. Nedergaard J, Cannon B. The browning of white adipose tissue: some burning issues. Cell Metab 2014;20:396-407.
47. Cypess AM, Weiner LS, Roberts-Toler C, Franquet EE, Kessler SH, Kahn PA, English J, Chatman K, Trauger SA, Doria A, Kolodny GM. Activation of human brown adipose tissue by a beta3-Adrenergic receptor agonist. Cell Metab 2015;21:33-38.
48. Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension 2012;59:893-898.
49. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-Adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 2004;369: 151-159.
50. Lobysheva II, Biller P, Gallez B, Beauloye C, Balligand JL. Nitrosylated hemoglobin levels in human venous erythrocytes correlate with vascular endothelial function measured by digital reactive hyperemia. PLoS One 2013;8:e76457.